Cargando…
Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial
OBJECTIVE: Vitiligo is a common, autoimmune disease that results in the destruction of the melanocytes and manifests as depigmented macules on various areas of the skin. Numerous treatment options have been proposed for vitiligo. The purpose of this study was to compare the efficacy of microneedling...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651420/ https://www.ncbi.nlm.nih.gov/pubmed/34887918 http://dx.doi.org/10.1155/2021/5652140 |
_version_ | 1784611392320438272 |
---|---|
author | Iraji, Fariba Asilian, Ali Talebzadeh, Zahra Saber, Mina Mokhtari, Fatemeh Siadat, Amirhossein Hosseini, Seyed Mohsen |
author_facet | Iraji, Fariba Asilian, Ali Talebzadeh, Zahra Saber, Mina Mokhtari, Fatemeh Siadat, Amirhossein Hosseini, Seyed Mohsen |
author_sort | Iraji, Fariba |
collection | PubMed |
description | OBJECTIVE: Vitiligo is a common, autoimmune disease that results in the destruction of the melanocytes and manifests as depigmented macules on various areas of the skin. Numerous treatment options have been proposed for vitiligo. The purpose of this study was to compare the efficacy of microneedling plus topical pimecrolimus 1% versus the sole use of topical pimecrolimus 1% for the treatment of vitiligo. METHODS: This clinical trial was conducted on 30 skin lesions on 15 Al-Zahra hospital patients. Each patient had two similar lesions in the limb area, and each lesion was considered a separate treatment group. The left or right side of the patient's lesion was randomly assigned to receive microneedling plus topical pimecrolimus for three months, while the other side received only topical pimecrolimus 1%. As part of the follow-up, digital photography was taken at the baseline and biweekly for three months after treatment and six months' follow-up. The following methods were used to evaluate the results: DLQI questionnaires, patient satisfaction questionnaires, and two independent dermatologists comparing the improvement rate for each group. RESULTS: Topical pimecrolimus 1% treatment led to unsatisfactory results, whereas the combination of microneedling and topical pimecrolimus1% treatment produced a more favorable overall outcome (P < 0.001). CONCLUSION: This study established that combination therapy results in more significant patient improvement. Additionally, one patient experienced mild skin irritation as a side effect of topical pimecrolimus. |
format | Online Article Text |
id | pubmed-8651420 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-86514202021-12-08 Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial Iraji, Fariba Asilian, Ali Talebzadeh, Zahra Saber, Mina Mokhtari, Fatemeh Siadat, Amirhossein Hosseini, Seyed Mohsen Dermatol Res Pract Research Article OBJECTIVE: Vitiligo is a common, autoimmune disease that results in the destruction of the melanocytes and manifests as depigmented macules on various areas of the skin. Numerous treatment options have been proposed for vitiligo. The purpose of this study was to compare the efficacy of microneedling plus topical pimecrolimus 1% versus the sole use of topical pimecrolimus 1% for the treatment of vitiligo. METHODS: This clinical trial was conducted on 30 skin lesions on 15 Al-Zahra hospital patients. Each patient had two similar lesions in the limb area, and each lesion was considered a separate treatment group. The left or right side of the patient's lesion was randomly assigned to receive microneedling plus topical pimecrolimus for three months, while the other side received only topical pimecrolimus 1%. As part of the follow-up, digital photography was taken at the baseline and biweekly for three months after treatment and six months' follow-up. The following methods were used to evaluate the results: DLQI questionnaires, patient satisfaction questionnaires, and two independent dermatologists comparing the improvement rate for each group. RESULTS: Topical pimecrolimus 1% treatment led to unsatisfactory results, whereas the combination of microneedling and topical pimecrolimus1% treatment produced a more favorable overall outcome (P < 0.001). CONCLUSION: This study established that combination therapy results in more significant patient improvement. Additionally, one patient experienced mild skin irritation as a side effect of topical pimecrolimus. Hindawi 2021-11-30 /pmc/articles/PMC8651420/ /pubmed/34887918 http://dx.doi.org/10.1155/2021/5652140 Text en Copyright © 2021 Fariba Iraji et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Iraji, Fariba Asilian, Ali Talebzadeh, Zahra Saber, Mina Mokhtari, Fatemeh Siadat, Amirhossein Hosseini, Seyed Mohsen Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial |
title | Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial |
title_full | Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial |
title_fullStr | Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial |
title_full_unstemmed | Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial |
title_short | Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial |
title_sort | microneedling in combination with topical pimecrolimus 1% versus topical pimecrolimus 1% for the treatment of refractory stable vitiligo: a randomized clinical trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651420/ https://www.ncbi.nlm.nih.gov/pubmed/34887918 http://dx.doi.org/10.1155/2021/5652140 |
work_keys_str_mv | AT irajifariba microneedlingincombinationwithtopicalpimecrolimus1versustopicalpimecrolimus1forthetreatmentofrefractorystablevitiligoarandomizedclinicaltrial AT asilianali microneedlingincombinationwithtopicalpimecrolimus1versustopicalpimecrolimus1forthetreatmentofrefractorystablevitiligoarandomizedclinicaltrial AT talebzadehzahra microneedlingincombinationwithtopicalpimecrolimus1versustopicalpimecrolimus1forthetreatmentofrefractorystablevitiligoarandomizedclinicaltrial AT sabermina microneedlingincombinationwithtopicalpimecrolimus1versustopicalpimecrolimus1forthetreatmentofrefractorystablevitiligoarandomizedclinicaltrial AT mokhtarifatemeh microneedlingincombinationwithtopicalpimecrolimus1versustopicalpimecrolimus1forthetreatmentofrefractorystablevitiligoarandomizedclinicaltrial AT siadatamirhossein microneedlingincombinationwithtopicalpimecrolimus1versustopicalpimecrolimus1forthetreatmentofrefractorystablevitiligoarandomizedclinicaltrial AT hosseiniseyedmohsen microneedlingincombinationwithtopicalpimecrolimus1versustopicalpimecrolimus1forthetreatmentofrefractorystablevitiligoarandomizedclinicaltrial |